Life science companies are often challenged to meet forecasts and maximize the growth of their therapies at any cost – with gross-to-net (GTN) often taking the biggest hit. In today’s market conditions, manufacturers can no longer afford to overlook GTN when building and scaling a patient access strategy. Read this white paper to discover the ultimate playbook for aligning the internal teams that have a stake in your brand’s success - including marketing, sales, market access, and patient services - to balance maximum patient access with a sustainable GTN.
Core elements, trends, and challenges of GTN growth for life sciences brands
Why GTN matters for your internal teams and aligning on shared vision of success
Key strategies to optimize patient access through a GTN lens
Success metrics to determine the efficacy of your access program on GTN
Your GTN potential is only as strong as your access partner. We’ve helped dozens of brands optimize their commercialization plans, and we’d love to help your brand do the same. To learn more about how the PhilRx patient access platform can support your brand, book a meeting with our team.
Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance.